Lv2
127 积分 2021-05-18 加入
Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study
2天前
已完结
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
3天前
已完结
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
3天前
已完结
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
3天前
已完结
Autophagolysosomal exocytosis inverts Src kinase onto the cell surface in cancer
4天前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
5天前
已完结
Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG
9天前
已完结
Ovarian cancer
11天前
已完结
Acquired on-target alterations drive clinical resistance to p53-Y220C reactivators
15天前
已完结
Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors
15天前
已完结
皖公网安备34019202002308
